Miaser ® is an antidepressant preparation that belongs to the group of Piperazine-azepine compounds. In the chemical structure of mianserin (the active component of the preparation) there is no side chain characteristic of tricyclic antidepressants, which causes the anticholinergic activity of the latter. Mianserin increases central noradrenergic neurotransmission by alpha 2 -auto receptor blockade and inhibition of norepinephrine reuptake. The preparation binds to serotonin receptors in the central nervous system. The antidepressant effect of Miaseru ® is similar to that of other modern antidepressants. In addition, the preparation also has a pronounced anxiolytic effect, which is important in the treatment of patients with depression associated with anxiety. The sedative effect of Miaseru®, associated with its effect on alpha 1 -adrenergic receptors and histamine H 1 receptors, is a good reason for using the preparation for sleep disorders against a background of depression.
Miaser ® is well tolerated by patients, including the elderly and patients with cardiovascular diseases. When used in therapeutic doses, it practically does not have anticholinergic activity and, accordingly, does not disrupt the functioning of the cardiovascular system.
In case of an overdose, Miaser® causes significantly less cardiotoxic effects in comparison with tricyclic antidepressants. The preparation does not interact with sympathomimetic and antihypertensive preparations, the action of which is due to the effects of beta-adrenergic receptors (betanidine) or alpha-adrenergic receptors (clonidine, methyldopa).
Depressive states of various origins.
Manic states, severe liver dysfunctions.
Method of administration and dosage
Miaser tablets should be taken orally, swallowed without chewing, with water.
The dose of the preparation is determined by the doctor individually for each patient.
For adults, the recommended starting dose of Miaseru® is 30 mg per day. The dose can be gradually increased every 3-4 days for optimal clinical response. As a rule, the effective daily dose of Miaseru® is 60-90 mg, the maximum is 90 mg.
Treatment of elderly patients begins with a dose of 30 mg per day. In the future, the dose of Miasera ® can be gradually increased. The maintenance effective daily dose of the preparation may be slightly lower than the usual dose for adults.
The daily dose of Miasera ® can be divided into several doses, but it is better to take the preparation in one dose in the evening, given its beneficial effect on night sleep.
Treatment with adequate doses of Miaseru® should lead to tangible positive results within 2-4 weeks of therapy. If the response is insufficient, the daily dose can be increased. If no positive effect is observed within the next 2-4 weeks, treatment with Miaser should be discontinued.
After the achieved clinical improvement, in order to maintain the positive effect of treatment with Miaser®, it should be continued for another 4-6 months.
Discontinuation of treatment rarely causes withdrawal symptoms.
Symptoms of a significant excess of the recommended doses of Miaseru ® are generally limited to prolonged sedation. Cardiac arrhythmias, seizures, severe arterial hypotension and respiratory depression are rare.
Treatment. There is no specific antidote. Gastric lavage is recommended, followed by symptomatic therapy and maintenance of the basic vital functions of the body.
active substance: mianserin;
1 tablet contains mianserin hydrochloride - 10 mg
Excipients: calcium hydrogen phosphate dihydrate, methylcellulose, colloidal silicon dioxide, magnesium stearate, corn starch, purified water
film shell: sepifilm 752 white (hypromellose, microcrystalline cellulose, polyoxyl 40 stearate, titanium dioxide), macrogol 8000, purified water.
Store in original packaging at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf life is 3 years.
There are no reviews for this product.